|
In animal studies, a new class of cholesterol-lowering
drugs called SCAP ligands appears
to be more potent and acts differently and perhaps
more effectively than statins.
High blood levels of low-density lipoprotein
(LDL), or "bad" cholesterol, greatly increase the
risk of heart disease and stroke, and cholesterol-lowering
drugs such as statins are sometimes prescribed to lower cholesterol
and reduce this risk.
SCAP ligands reduce cholesterol and triglycerides
by up to 80% in hamsters, which process cholesterol similarly
to humans. Statin drugs have been found to reduce LDL cholesterol
by only 60% and triglycerides by 30% in humans.
According to the investigators, both
statins and SCAP ligands increase the number of LDL receptors,
which "mop up" cholesterol from the blood; the more
LDL receptors, the lower the cholesterol level.
Statins and SCAP ligands appear to work
differently. Statins indirectly increase the number of LDL
receptors by blocking the body's cholesterol production; this
in turn raises the number of LDL receptors. In contrast, SCAP
ligands directly increase the number of LDL receptors without
first blocking cholesterol production.
Because of their "direct" action,
SCAP ligands cause a potent and sustained reduction of both
LDL cholesterol and triglycerides.
The
safety of these compounds will need to be carefully evaluated.
Nature
Medicine December 2001;7:1282-1284, 1332-1338
|